Detection of 1,3-β-d-glucan (BDG) in serum has been evaluated for its inclusion as a mycological criterion of invasive fungal infections (IFI) according to EORTC and Mycoses Study Group (MSG) definitions. BDG testing may be useful for the diagnosis of both invasive aspergillosis and invasive candidiasis, when interpreted in conjunction with other clinical/radiological signs and microbiological markers of IFI. However, its performance and utility vary according to patient population (hematologic cancer patients, solid-organ transplant recipients, intensive care unit patients) and pretest likelihood of IFI. The objectives of this article are to provide a systematic review of the performance of BDG testing and to assess recommendations for its use and interpretation in different clinical settings.

Ankara University Faculty of Medicine Cebeci Campus Hematology Clinical Research Unit Ankara Turkey

Department of Medicine and Microbiology and Immunology University of Wisconsin Madison Wisconsin USA

Department of Medicine Ensemble Hospitalier de La Côte Morges Switzerland

Division of Infectious Diseases McGovern Medical School Houston Texas USA

Division of Infectious Diseases University of Pittsburgh Pittsburgh Pennsylvania USA

Infectious Diseases Service Lausanne University Hospital and University of Lausanne Lausanne Switzerland

Infectious Diseases Unit G Fracastoro Hospital San Bonifacio Verona Italy

Institute of Hematology and Blood Transfusion Prague Czech Republic

Institute of Microbiology Lausanne University Hospital and University of Lausanne Lausanne Switzerland

Citace poskytuje Crossref.org